

ZIOPHARM ONCOLOGY INC  
Form 8-K  
September 20, 2006

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

**FORM 8-K**

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF  
THE SECURITIES EXCHANGE ACT OF 1934

Date of report (date of earliest event reported): September 20, 2006

**ZIOPHARM Oncology, Inc.**

(Exact name of registrant as specified in its charter)

Delaware	0-32353	84-1475642
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

**1180 Avenue of the Americas, 19<sup>th</sup> Floor**  
**New York, NY 10036**

(Address of principal executive offices) (Zip Code)

**(646) 214-0700**

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01. Other Events.**

On September 20, 2006, the Company issued a press release announcing that it had received approval for its application to list its common shares on The NASDAQ Capital Market. The Company's common shares will begin trading on The NASDAQ Capital Market on Friday, September 22, 2006 under the symbol "ZIOP." The trading of ZIOPHARM's shares on the Over-the-Counter Bulletin Board will cease at the close of business on Thursday, September 21, 2006.

**Item 9.01 Financial Statements and Exhibits.**

	(d)	Exhibits.
99.1		Press Release dated September 20, 2006.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 20, 2006

**ZIOPHARM Oncology, Inc.:**  
(REGISTRANT)

By: /s/ Richard E. Bagley

\_\_\_\_\_  
RICHARD E. BAGLEY, President,  
*Chief Operating Officer and Chief Financial Officer*

Exhibit Index

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release date September 20, 2006

---